Unadjusted and adjusted OR for an improved GBS disability score at 4 and 26 weeks
| N | Unadjusted OR (95% CI) | P value | N | Adjusted OR* (95% CI) | P value | |
| Week 4 | ||||||
| Treatment | ||||||
| Supportive care | 34 | 1.0 (ref.) | 27 | 1.0 (ref.) | ||
| IVIg | 129 | 0.69 (0.33 to 1.43) | 0.32 | 98 | 1.62 (0.63 to 4.13) | 0.32 |
| Week 26 | ||||||
| Treatment | ||||||
| Supportive care | 30 | 1.0 (ref.) | 25 | 1.0 (ref.) | ||
| IVIg | 121 | 0.75 (0.35 to 1.62) | 0.47 | 97 | 0.65 (0.24 to 1.78) | 0.41 |
*Adjusted for: age, ataxia at entry, autonomic dysfunction at entry, diarrhoea, region, GBS disability score at entry, MRC sum score at entry, axonal subtype, improvement on the MRC sum score.
GBS, Guillain-Barré syndrome; IVIg, intravenous immunoglobulin; MRC, Medical Research Council.